Aenova Group

What Aenova Group does

Aenova Group is one of the international service providers in the pharmaceuticals and health care industry. Driven by its high standards of quality, innovative technology and a clear orientation to the future, it has evolved into Europe’s leading operator in the development, manufacture and marketing of pharmaceuticals and dietary supplements. Its range comprises solid dosage forms such as soft and hard capsules, tablets, film-coated tablets, dragées and effervescent tablets.

Name

Aenova Group

Legal name

Aenova Holding GmbH

Website

http://www.aenova-group.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Aenova Group is a suppiler of pharmaceutical and healthcare services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical contract manufacturing
• Drug formulation development
• Sterile injectables manufacturing
• Animal health manufacturing
• Finished dosage forms

Headquarters

HQ city

Greensboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Aenova generates revenue through contract pharmaceutical manufacturing services, providing development and manufacturing capabilities for finished dosage forms and sterile products for pharmaceutical and healthcare companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aenova Group is a pharmaceutical contract development and manufacturing organization (CDMO) that produces solid, semi-solid, liquid, and sterile dosage forms including tablets, capsules, softgels, and injectable drugs. The company serves pharmaceutical and animal health customers with end-to-end services spanning formulation development, analytical services, technology transfer, and commercial-scale manufacturing. It also operates the Aenovation program to accelerate formulation projects and a dedicated animal health manufacturing line.

Product overview

Aenova Group is a worldwide leading contract manufacturer and development organization for the pharmaceutical and healthcare industry. The company operates a multi-module platform offering three integrated service lines: Pharmaceutical Manufacturing (covering tablets, capsules, softgels, sterile injectables, and effervescent products), Development & Technology (formulation development and analytical services), and Animal Health (veterinary pharmaceutical products). The portfolio includes the Aenovation formulation acceleration program as an add-on service to accelerate client drug development timelines.

Differentiator

Problem solved

Functional benefit

Brands

• Aenovation: Formulation acceleration program launched by Aenova to support drug development services market.

Products and services

• Pharmaceutical Manufacturing Contract manufacturing of solid, semi-solid, liquid, and sterile dosage forms including tablets, capsules, softgels, vials, and prefilled syringes for pharmaceutical customers.
• Development & Technology Formulation development, analytical services, and technology transfer support for pharmaceutical customers moving drug products from development to commercial manufacturing.
• Animal Health Dedicated contract manufacturing of veterinary pharmaceuticals and animal health products, including species-specific formulations.
• Aenovation An accelerated formulation development program that helps pharmaceutical customers reduce time-to-market by combining formulation, analytical, and regulatory expertise in a structured engagement.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• GalvitacoreStrategic or Co-development Partner · 1 July 2023In July 2023, US-based contract manufacturer Aenova Group partnered with Galvita to advance the development and production of oral dosage forms tailored for dysphagia patients. The partnership focuses on specialized oral nutritional supplements and medication for patients with swallowing difficulties.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Siegfried Holding: Swiss-listed pharmaceutical CDMO offering API and finished dosage form manufacturing across oral solids, sterile and niche categories. Directly comparable in scale, European footprint and small-molecule CDMO positioning.
• Recipharm: Swedish-headquartered pharmaceutical CDMO with strong European manufacturing base across solid, semi-solid, sterile and biologics. Direct competitor in finished dosage forms and sterile fill-finish for European pharma clients.
• Fareva: French privately-held pharmaceutical CDMO with broad European manufacturing footprint spanning oral solids, sterile injectables, and topical formulations. Closely comparable mid-sized private European CDMO competitor.
• CordenPharma: CDMO owned by International Chemical Investors Group, offering API and drug product manufacturing including sterile injectables and oral solids. Direct competitor in small-molecule and peptide CDMO services in Europe.
• Hovione: Portuguese privately-held CDMO specialising in API manufacturing, particle engineering and drug product services. Comparable in integrated CDMO service model with strong European base and private ownership.

Broad incumbents

• Lonza Group: Swiss-listed global leader in CDMO services with dominant scale across biologics, cell & gene therapy and small molecules. Operates in many of the same pharmaceutical CDMO categories as Aenova but at substantially larger scale.
• Catalent: US-headquartered global CDMO (acquired by Novo Holdings in 2024) with broad capabilities including softgel, oral solids, sterile injectables and biologics. Direct competitor in softgel and sterile fill-finish with global reach.
• Thermo Fisher Scientific (Patheon): Operates Patheon pharmaceutical CDMO services offering API, oral solid, sterile and biologics manufacturing globally. Broad incumbent with overlapping small-molecule and sterile CDMO capabilities.

Emerging players

• WuXi STA: Chinese CDMO with rapidly expanding global footprint offering API and drug product services. Emerging player whose scale-up trajectory reflects industry consolidation dynamics relevant to Aenova's positioning.
• Alcami Corporation: US-headquartered CDMO offering sterile injectables, oral solids and API development. Comparable in mid-scale contract manufacturing services, particularly in sterile fill-finish.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/aenovagroup
• LinkedInlinkedin.com/company/aenova-swiss-caps
• Instagraminstagram.com/aenova_group

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aenova Group